Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Targeted Therapy
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Dosing Strategy
100%
Dose Optimization
100%
Advanced Renal Cell Carcinoma (aRCC)
100%
Targeted Agents
66%
Exclusion Criteria
33%
Sunitinib
16%
Sorafenib
16%
Patient Demographics
16%
Vascular Endothelial Growth Factor
16%
Interferon-α (IFN-α)
16%
Adverse Events
16%
Treatment Options
16%
Standard of Care
16%
Progression-free Survival
16%
Interleukin-2
16%
Bevacizumab
16%
New Therapies
16%
Therapeutic Implications
16%
Cytokine Therapy
16%
Dose Administration
16%
Dose Adjustment
16%
Dosing Scheme
16%
Pazopanib
16%
Growth Factor Pathway
16%
Real Patients
16%
Everolimus
16%
Temsirolimus
16%
Axitinib
16%
Alternative Dosing
16%
Mammalian Target of Rapamycin Signaling Pathway
16%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Targeted Therapy
100%
Kidney Metastasis
100%
Clinical Study
16%
Patient Population
16%
Vasculotropin
16%
Interleukin 2
16%
Interferon
16%
Progression Free Survival
16%
Medication Compliance
16%
Sunitinib
16%
Cytokine Therapy
16%
Sorafenib
16%
Mechanistic Target of Rapamycin
16%
Pazopanib
16%
Bevacizumab
16%
Everolimus
16%
Temsirolimus
16%
Axitinib
16%
Treatment Option
16%
Exclusion Criterion
16%
Adverse Event
16%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Kidney Metastasis
100%
Cytokine
16%
Clinical Study
16%
Adverse Event
16%
Sorafenib
16%
Sunitinib
16%
Progression Free Survival
16%
Interleukin 2
16%
Interferon
16%
Bevacizumab
16%
Vasculotropin
16%
Mammalian Target of Rapamycin
16%
Pazopanib
16%
Everolimus
16%
Temsirolimus
16%
Axitinib
16%